M&A Deal Summary |
|
|---|---|
| Date | 2019-11-18 |
| Target | Avizorex Pharma SL |
| Sector | Life Science |
| Buyer(s) | Aerie |
| Deal Type | Add-on Acquisition |
| Deal Value | 10M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Revenue | 194M USD (2021) |
Aerie is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie was founded in 2005 and is based in Durham, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Spain M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |